Sugi Predict

Sugi Predict / Compounds / SCHEMBL1973251

SCHEMBL1973251

SCHEMBL1973251

O=C1c2ccccc2C(=O)N1c1ccc([N+](=O)[O-])cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SCN2A Q99250 4/20 1.00
▸ CA12 O43570 6/20 0.57
▸ CA9 Q16790 6/20 0.57
▸ CA1 P00915 5/20 0.57
▸ CA2 P00918 5/20 0.57
▸ MEN1 O00255 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ AR P10275 1/20 0.54
▸ ALDH1A1 P00352 2/20 0.50
▸ GAA P10253 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ PKM P14618 1/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ RECQL P46063 1/20 0.49
▸ IDO1 P14902 1/20 0.49
▸ TDO2 P48775 1/20 0.49
▸ LMNA P02545 1/20 0.48
▸ CTDSP1 Q9GZU7 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30118348 1.00 SCN2A (1.00) SCN2ACA12CA9CA1CA2
SCHEMBL12556940 0.85 SCN2A (0.74) SCN2ACA12CA9CA1CA2
SCHEMBL406359 0.83 CA12 (0.72) SCN2ACA12CA9CA1CA2
SCHEMBL11647318 0.82 SCN2A (0.69) SCN2ACA12CA9CA1CA2
SCHEMBL27324560 0.82 SCN2A (0.69) SCN2ACA12CA9CA1CA2
SCHEMBL5707683 0.82 SCN2A (0.69) SCN2ACA12CA9CA1CA2
SCHEMBL4649471 0.82 KMT2A (0.78) SCN2ACA12CA9CA1CA2
SCHEMBL11669113 0.81 SCN2A (1.00) SCN2ACA12CA9CA1CA2
SCHEMBL30758587 0.81 SCN2A (1.00) SCN2ACA12CA9CA1CA2
SCHEMBL17326265 0.80 SCN2A (0.67) SCN2ACA12CA9CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114806009-B Electret master batch for melt-blown electret and preparation method and application thereof 河南省驼人医疗科技有限公司 2023-06-20 — — CN claimed
CN-115448868-A Method for strengthening catalytic hydrogenation reaction of nitro compound 青海黄河上游水电开发有限责任公司西宁太阳能电力分公司 2022-12-09 — — CN claimed
CN-117569073-A Melt-blown non-woven fabric and preparation method and application thereof 深圳市芥至和生物科技有限公司 2024-02-20 — — CN disclosed
CN-117466799-A Preparation method of N-substituted phthalimide compound 西北师范大学 2024-01-30 — — CN disclosed
CN-115448868-B Method for strengthening catalytic hydrogenation reaction of nitro compound 青海黄河上游水电开发有限责任公司西宁太阳能电力分公司 2024-01-26 — — CN disclosed
CN-116751137-A Method for preparing chloro aromatic compound by photo-induced nitroarene denitration chlorination 华中师范大学 2023-09-15 — — CN disclosed
CN-113789580-B Electret polypropylene melt-blown material and preparation method and application thereof 北京伊士通新材料发展有限公司 2023-08-22 — — CN disclosed
CN-114806009-B Electret master batch for melt-blown electret and preparation method and application thereof 河南省驼人医疗科技有限公司 2023-06-20 — — CN disclosed
CN-112745578-B High-efficiency low-resistance melt-blown material and preparation process thereof 称道新材料科技(上海)有限公司 2023-04-14 — — CN disclosed
CN-115448868-A Method for strengthening catalytic hydrogenation reaction of nitro compound 青海黄河上游水电开发有限责任公司西宁太阳能电力分公司 2022-12-09 — — CN disclosed
CN-114806009-A Electret master batch for melt-blown electret, preparation method and application thereof 河南省驼人医疗科技有限公司 2022-07-29 — — CN disclosed
WO-2010033349-A1 PHTHALIMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS MERCK & CO., INC. (US) 2010-03-25 — — WO disclosed
WO-2010033349-A1 PHTHALIMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS MERCK & CO., INC. (US) 2010-03-25 — — WO disclosed
US-7622474-B2 Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis PORTOLA PHARMACEUTICALS, INC. (US) 2009-11-24 — — US disclosed
US-20080194597-A1 Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis PORTOLA PHARMACEUTICALS, INC. (US) 2008-08-14 — — US disclosed
US-7358257-B2 sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents PORTOLA PHARMACEUTICALS, INC. (US) 2008-04-15 — — US disclosed
EP-1047672-B1 PROCESS FOR PREPARING SPARINGLY SOLUBLE AROMATIC AMINES CIBA SC HOLDING AG (CH) 2005-06-22 — — EP disclosed
EP-1047672-A1 PROCESS FOR PREPARING SPARINGLY SOLUBLE AROMATIC AMINES Ciba SC Holding AG (CH) 2000-11-02 — — EP disclosed
US-6087480-A Process for preparing sparingly soluble aromatic amines CIBA SPECIALTY CHEMCALS CORPORATION (US) 2000-07-11 — — US disclosed
WO-1999036402-A1 PROCESS FOR PREPARING SPARINGLY SOLUBLE AROMATIC AMINES CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 1999-07-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194597-A1 Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis PIGS, GP6, ASGR1 SCN2A 320/4885CA12 4701/4885CA9 1451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.